Clinical trials: Immunization
HIV Infections
Induction and Expansion of T Cell Repertoire Using Growth Hormone and Vaccination in HIV-1 Infected Patients
Concomitant administration of recombinant human growth hormone (rhGH) may boost the expansion of immune reconstitution and broaden specific T cell responses not achievable by vaccination alone.
- Trial name
- NCT00287677
- Testing
- recombinant human Growth Hormone, Vaccination, HAART
- Where
- 2 sites in Spain
- Volunteers
- 33 people, healthy volunteers welcome
- Sponsor
- Germans Trias i Pujol Hospital
Efficacy of the New CPRV
Immune Response in Adults to PrEP and Simulated Booster PEP With a New CPRV
Pre exposure rabies vaccination with a new Chromatographically Purified Vero-cell Rabies Vaccine(SPEEDA) is as effective as Purified Vero-cell Rabies vaccine.
- Trial name
- NCT01603875
- Testing
- New Chromatographically Purified Vero-cell Rabies vaccine(new CPRV).
- Where
- Thailand
- Volunteers
- 105 people, healthy volunteers welcome
- Sponsor
- Queen Saovabha Memorial Institute
Hepatitis B
Safety and Immunogenicity of a Booster Dose of GlaxoSmithKline (GSK) Biologicals' Hepatitis B Vaccine
In this study, subjects who received primary neonatal vaccination with hepatitis B vaccine at 0, 1, 2, 12 months, 20 years ago in the 103860/272 primary study will be evaluated for immunological memory to hepatitis B vaccine via…
- Trial name
- NCT00657657
- Testing
- Engerix™-B
- Where
- Thailand
- Volunteers
- 29 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Influenza
Inactivated Split Virus Seasonal Influenza Vaccine (Vero Cell-Derived)
The purpose of this study is to determine if a Vero cell-derived trivalent seasonal influenza vaccine produced by the modified manufacturing process: 1.
- Trial name
- NCT01773928
- Testing
- Vero cell-derived trivalent influenza vaccine manufactured with the modified manufacturing process (VCIV modified), VCIV manufactured with the current manufacturing process (VCIV current), Fluzone®, licensed trivalent influenza vaccine (TIV)
- Where
- 20 sites in United States
- Volunteers
- 1,928 people, healthy volunteers welcome
- Sponsor
- Alachua Government Services, Inc.
Renal Cell Carcinoma, GIST
Study of the Immunoresponse in Patients Treated With a Tyrosine Kinase Inhibitor
In this study the researchers investigate the influence of the tyrosine kinase inhibitors sunitinib and sorafenib, on the normal humoral and cellular immuno response to influenza vaccination in patients with metastases of renal…
- Trial name
- NCT00979381
- Testing
- influenza vaccine
- Where
- Netherlands
- Volunteers
- 75 people, healthy volunteers welcome
- Sponsor
- Radboud University Medical Center
Japanese Encephalitis Vaccine
Immunogenicity, Safety, and Antibody Persistence of Different Immunization Strategies Against Japanese Encephalitis
The main objective of this study is to evaluate the persistence of Japanese encephalitis antibodies in participants at the age of 6, after they have followed different Japanese encephalitis vaccination schedules.
- Trial name
- NCT06825312
- Testing
- Japanese Encephalitis Vaccine (Vero Cell), Inactivated, Japanese Encephalitis Vaccine, Live
- Where
- 6 sites in China
- Volunteers
- 600 people, healthy volunteers welcome
- Sponsor
- Liaoning Chengda Biotechnology CO., LTD
Meningococcal Disease, Invasive
Adolescent MenACWY Booster Study
This study is to confirm non-inferiority of the three MenACWY vaccines (Menveo, Menactra or Nimenrix) in adolescents, and to identify whether the number of previous doses of MenC influences the response to the MenACWY vaccine.
- Trial name
- NCT03694405
- Testing
- MenACWY-CRM, MenACWY-DT, MenACWY-TT
- Where
- 3 sites in Canada
- Volunteers
- 244 people, healthy volunteers welcome
- Sponsor
- Canadian Immunization Research Network
Japanese Encephalitis
Rapid Immunization Study of the Japanese Encephalitis Vaccine IC51
The study investigates a rapid immunization regime of the Japanese Encephalitis vaccine IC51 (JE-PIV) in healthy subjects aged > or = 18 years
- Trial name
- NCT00595790
- Testing
- IC51
- Volunteers
- 374 people, healthy volunteers welcome
- Sponsor
- Valneva Austria GmbH
Whooping Cough
Vouchers to Promote Tdap Vaccination
This study is a small-scale randomized, placebo-controlled factorial trial of two interventions to increase Tetanus, diphtheria and acellular pertussis (Tdap) immunization rates among infant caregivers.
- Trial name
- NCT01860378
- Testing
- Full price, $5 off
- Where
- United States
- Volunteers
- 149 people, healthy volunteers welcome
- Sponsor
- Children's Hospital of Philadelphia
Influenza
Feasibility of Randomizing Danish Citizens Aged 65-79 Years to High-Dose Quadrivalent Influenza Vaccine vs. Standard-Dose Quadrivalent Influenza Vaccine in a Pragmatic Registry-Based Setting
The purpose of the study is to assess the feasibility of identifying, recruiting and randomizing a large sample of Danish citizens aged 65-79 years to high-dose quadrivalent influenza vaccine or standard-dose quadrivalent…
- Trial name
- DANFLU-1 (NCT05048589)
- Testing
- Standard-Dose Quadrivalent Influenza Vaccine, High-Dose Quadrivalent Influenza Vaccine
- Where
- 2 sites in Denmark
- Volunteers
- 12,551 people, healthy volunteers welcome
- Sponsor
- Tor Biering-Sørensen
Smallpox
Dose Study of ACAM2000 Smallpox Vaccine in Previously Vaccinated Adults
The objective of this study is to determine the minimum dose of ACAM2000 needed to produce a cutaneous reaction in at least 90% of a population of healthy adults at least 28 years of age and previously vaccinated against smallpox.
- Trial name
- NCT00053482
- Testing
- ACAM2000 Smallpox Vaccine, Vaccinia virus (calf lymph) smallpox vaccine: Dryvax®
- Where
- 3 sites in United States
- Volunteers
- 357 people, healthy volunteers welcome
- Sponsor
- Emergent BioSolutions
Vaccination Adverse Events, Vaccination Failure
Safety, Immunogenicity And Efficacy Of Vaccination In Military Personnel
The purpose of this study is to determine if multiple vaccination in military personnel may be correlated with the appearance of poorly defined diseases as symptomatic multisyndrome, autoimmune or lymphoproliferative disorders.
- Conditions
- Vaccination Adverse Events, Vaccination Failure, Specific Antibody Response
- Trial name
- NCT01807780
- Testing
- biological monitoring
- Where
- Italy
- Volunteers
- 262 people, healthy volunteers welcome
- Sponsor
- University of Roma La Sapienza
Hepatitis B Vaccines
Study of the Long Term Efficacy of Recombinant Hepatitis B Vaccine in Nile Delta of Egypt
More than two billion individuals have serological evidence of hepatitis B virus (HBV) infection worldwide. Of these, 240 million are chronic carriers and approximately 786,000 hepatitis B related deaths occur annually.
- Trial name
- NCT02797782
- Testing
- Detection of anti HBs antibody titer
- Where
- Egypt
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Sherief Abd-Elsalam
Healthy
AI Chatbot for HPV Vaccine Literacy Among Caregivers in Japan
The goal of this study is to learn if an innovative digital artificial intelligence (AI)-based communication tool works to enhance health literacy among Japanese caregivers regarding Human Papillomavirus (HPV) vaccination.
- Trial name
- NCT06702423
- Testing
- AI-based chatbot, Leaflet
- Where
- United Kingdom
- Volunteers
- 804 people, healthy volunteers welcome
- Sponsor
- The University of Hong Kong
Varicella
Evaluate the Safety and Immunogenicity After MG1111(BARICELA Inj.) as 2nd Vaccination in 4 ~ 6 Year Old Healthy Children With a History of 1st Varicella Vaccination
Primary objective is to assess the safety of MG1111 until Day 42 using as 2nd vaccination Secondary objective to assess the immunogenicity and safety of MG1111 using as 2nd vaccination
- Trial name
- NCT05422508
- Testing
- MG1111 (BARICELA), VARIVAX, Suduvax
- Where
- South Korea
- Volunteers
- 230 people, healthy volunteers welcome
- Sponsor
- Green Cross Corporation
Pneumococcal Infections
Mother's Gift Project
This prospective randomized evaluation of pneumococcal vaccine immunization of pregnant mothers, followed by pneumococcal conjugate immunization of their children is designed to assess the effects of these strategies on the…
- Trial name
- NCT00142389
- Testing
- pneumococcal polysaccharide and protein conjugate vaccines
- Where
- Bangladesh
- Volunteers
- 680 people, healthy volunteers welcome
- Sponsor
- Johns Hopkins Bloomberg School of Public Health
Polio, Immunization; Infection
Community Engagement and Conditional Incentives to Accelerate Polio
Immunization is one of the most cost-effective and successful public health strategy in reducing the health, economic and societal burden of many infectious diseases.
- Conditions
- Polio, Immunization; Infection, Incentives
- Trial name
- GLIDE (NCT05721274)
- Testing
- Community mobilization and Conditional community incentives
- Where
- Pakistan
- Volunteers
- 840 people, healthy volunteers welcome
- Sponsor
- Aga Khan University
Chlamydia Trachomatis Immunization
Phase 1/2 Study of Chlamydia Trachomatis mRNA Vaccine in Adults Aged 18 to 29 Years
The purpose of this study is to evaluate the safety, efficacy, and immunogenicity of different dose levels (low, medium, and high) of Chlamydia messenger ribonucleic acid (mRNA) Vaccine candidate in adult participants aged 18 to…
- Trial name
- NCT06891417
- Testing
- Chlamydia mRNA Vaccine
- Where
- 7 sites in Australia
- Volunteers
- 1,560 people, healthy volunteers welcome
- Sponsor
- Sanofi
Vaccination Refusal
An Adaptive Prenatal Intervention to Increase Childhood Vaccinations
This study will test whether proactively connecting expectant parents with factual vaccination information during pregnancy can build confidence in vaccinations and lead to timely vaccinations during pregnancy and once their…
- Trial name
- ADEPT (NCT05795855)
- Testing
- ADEPT
- Where
- United States
- Volunteers
- 770 people, healthy volunteers welcome
- Sponsor
- Emory University
COVID-19
A Clinical Trial of Recombinant COVID-19 Bivalent (XBB+Prototype) Protein Vaccine (Sf9 Cell) in Booster Vaccination
A Clinical Trial of Recombinant COVID-19 Bivalent (XBB+Prototype) Protein Vaccine (Sf9 Cell) in Booster Vaccination to evaluate safety and immunogenicity in healthy population aged 18 years old and above.
- Trial name
- NCT05911048
- Testing
- Recombinant COVID-19 Bivalent (XBB+Prototype) Protein Vaccine (Sf9 Cell) (WSK-V101C), Recombinant COVID-19 vaccine(Sf9 Cell) (WSK-V101)
- Volunteers
- 3,100 people, healthy volunteers welcome
- Sponsor
- WestVac Biopharma Co., Ltd.